Alzheimer’s drugs ‘make no meaningful difference to patients,’ major review suggests
Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK...
Redirecting to full article...
Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK...
Redirecting to full article...